On January 14, 2022, THELMA Therapeutics Co., Ltd closed the transaction. The company also amended the terms of the transaction. The company has now received KRW 2,800,000,000 in the transaction.

The bonds shall be convertible into 2,800,000 shares for 11.4% stake in the company.